Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.

Abstract:

:Preliminary results of a phase II study of gemcitabine plus trastuzumab in previously treated (up to 3 previous regimens) metastatic breast cancer patients are presented. Patients had histologically confirmed metastatic breast cancer, with 2+ or 3+ tumor HER2 expression. Treatment consisted of gemcitabine 1200 mg/m2 over 30 minutes intravenously on days 1 and 8 every 21 days, and trastuzumab 4 mg/kg over 90 minutes, followed by 2 mg/kg infused over 30 minutes weekly. Treatment was continued until disease progression or unacceptable toxicity occurred. Preliminary results are available on the first 38 patients enrolled. Median patient age was 53 years, 53% had estrogen receptor/progesterone receptor-positive disease, and HER2 staining was 2+ in 39% and 3+ in 61% of patients. There was a median of 3 previously administered (including adjuvant) chemotherapy regimens, and a median of 4.5 treatment cycles per patient has been administered so far. Twelve patients (32%) have had an objective partial response, with a median response duration of 8.6 months. Median time to disease progression is 6.7 months to date, with a median overall survival of 10.2 months. No unexpected toxicities or grade 4 nonhematologic toxicities have been observed; 2 patients developed grade 4 neutropenia and 1 patient had febrile neutropenia. Thus, gemcitabine/ trastuzumab resulted in an encouraging 32% response rate, given the heavily pretreated patient population. Tolerability was good overall, with no unexpected side effects observed.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

O'Shaughnessy J,Vukelja SJ,Marsland T,Kimmel G,Ratnam S,Pippen J

doi

10.3816/cbc.2002.s.004

keywords:

subject

Has Abstract

pub_date

2002-05-01 00:00:00

pages

17-20

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(11)70281-6

journal_volume

3 Suppl 1

pub_type

临床试验,杂志文章
  • Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

    abstract:BACKGROUND:Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemother...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2018.12.012

    authors: Ortega V,Antón A,Garau I,Afonso N,Calvo L,Fernández Y,Martínez-García M,Blanco E,Zamora P,García M,Illarramendi JJ,Rodríguez Sánchez CA,Sampayo M,Aguirre E,Pérez-García JM,Cortés J,Llombart-Cussac A

    更新日期:2019-04-01 00:00:00

  • Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

    abstract:BACKGROUND:We investigated the effect of basal protein expression on trastuzamab response in patients with HER2-positive (HER2(+)) breast cancer who received trastuzamab (T) and in HER2(+) breast cancer cell lines. PATIENTS AND METHODS:Expression of cytokeratin (CK) 5/6, CK14, and epidermal growth factor receptor (EGF...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.06.001

    authors: Chung A,Choi M,Han BC,Bose S,Zhang X,Medina-Kauwe L,Sims J,Murali R,Taguiam M,Varda M,Schiff R,Giuliano A,Cui X

    更新日期:2015-12-01 00:00:00

  • Role of Overweight, Obesity, and Comorbidities in the Prognosis of Patients With Breast Cancer With Brain Metastases.

    abstract:INTRODUCTION:Breast cancer (BC) is the most common cancer in women, and the incidence of brain metastasis (BM) from BC ranges from 20% to 30%, with a median survival of 10 to 15 months. Previous reports have shown that the presence of obesity or diabetes negatively impacts survival. The present study investigates the a...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2018.12.018

    authors: Cacho-Díaz B,Spínola-Maroño H,Reynoso N,González-Aguilar A,Mohar-Betancourt A

    更新日期:2019-04-01 00:00:00

  • Bisphosphonates as anticancer therapy for early breast cancer.

    abstract::Bisphosphonates (BPs) are approved for preventing the skeletal-related events associated with malignant bone disease. Several studies indicate that they may also prevent cancer therapy-induced bone loss. Multiple preclinical and early clinical studies provide evidence of the anticancer activity of BPs, including an in...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2010.n.047

    authors: Mahtani R,Jahanzeb M

    更新日期:2010-10-01 00:00:00

  • Delayed resolution of jaundice in the arm of a patient with impaired lymphatic drainage: a case report.

    abstract::A 40-year-old woman, 6 years after mastectomy, lymph node dissection, and locoregional radiation, presented with hepatic metastases, pruritus, and jaundice. Physical examination revealed uniformly jaundiced skin and no arm lymphedema. Ultrasonography confirmed progressive hepatic metastases with no evidence of intrahe...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2007.n.055

    authors: Tsang RY,Mackey JR

    更新日期:2007-12-01 00:00:00

  • The Role of Contrast-Enhanced Ultrasound in the Diagnosis and Pathologic Response Prediction in Breast Cancer: A Meta-analysis and Systematic Review.

    abstract:PURPOSE:To determine the overall performance of contrast-enhanced ultrasound (CEUS) in differentiating between benign and malignant breast lesions and in predicting the pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). MATERIALS AND METHODS:Articles published up to April 2019 w...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.03.002

    authors: Zhou SC,Le J,Zhou J,Huang YX,Qian L,Chang C

    更新日期:2020-08-01 00:00:00

  • Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.

    abstract:BACKGROUND:In this analysis we compared quality-adjusted survival outcomes between nab-paclitaxel (nab-P) and standard paclitaxel (Pac) using data from the nab-P phase III registration trial in metastatic breast cancer. PATIENTS AND METHODS:Quality-adjusted overall survival was estimated using the quality-adjusted tim...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.03.014

    authors: Cortes J,Pérez-García J,Whiting S,Wan Y,Solem C,Tai MH,Margunato-Debay S,Ko A,Fandi A,Botteman M

    更新日期:2018-10-01 00:00:00

  • Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.

    abstract:BACKGROUND:Nanoparticle albumin-bound paclitaxel (nab-P) and bevacizumab have each demonstrated efficacy in patients with MBC. This trial was designed to further develop nab-P by evaluating its efficacy and safety using every 3 weeks (q3w), every 2 weeks (q2w), or weekly scheduling in combination with bevacizumab as fi...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2013.02.008

    authors: Seidman AD,Conlin AK,Bach A,Moynahan ME,Lake D,Forero A,Wright GS,Hackney MH,Clawson A,Norton L,Hudis CA

    更新日期:2013-08-01 00:00:00

  • Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer.

    abstract::The sequential use of a doxorubicin combination followed by paclitaxel has been reported to improve disease-free and overall survival in patients with node-positive breast cancer beyond that obtained with doxorubicin/cyclophosphamide combinations. Epirubicin is associated with less cardiotoxicity than doxorubicin and ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2000.s.010

    authors: Perez EA

    更新日期:2000-09-01 00:00:00

  • Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic.

    abstract:BACKGROUND:Single-frequency bioelectrical impedance (BI) has been used to measure extracellular fluid in the upper limbs. The purpose of the study was to evaluate BI's ability to detect and monitor upper limb changes in based upon the extent of various treatments and to assess its practicality. METHODS:Patients with n...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2012.01.004

    authors: Vicini F,Shah C,Lyden M,Whitworth P

    更新日期:2012-04-01 00:00:00

  • Improved Performance of Adjunctive Ultrasonography After Mammography Screening for Breast Cancer Among Chinese Females.

    abstract:INTRODUCTION:Until now, no studies have investigated whether women other than those with dense breasts are suitable for adjunctive ultrasonography after negative mammography, and investigated whether all women with negative mammography are suitable for adjunctive ultrasonography. METHODS:Based on the Multi-modality In...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2017.07.014

    authors: Dong H,Huang Y,Song F,Dai H,Liu P,Zhu Y,Wang P,Han J,Hao X,Chen K

    更新日期:2018-06-01 00:00:00

  • Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

    abstract:INTRODUCTION:Dose-dense therapies have had a major effect on reducing toxicity and improving outcomes in breast cancer. A combination of TC every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to delive...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2013.10.018

    authors: Burkard ME,Wisinski KB,Njiaju UO,Donohue S,Hegeman R,Stella A,Mansky P,Shah V,Goggins T,Qamar R,Dietrich L,Kim K,Traynor AM,Tevaarwerk AJ

    更新日期:2014-06-01 00:00:00

  • A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care.

    abstract:INTRODUCTION:Unwanted clinical variation is common across the United States health care system and is particularly vexing in oncology owing to the complexity, morbidity, and high cost of the disease. Efforts to standardize care including guidelines and continuing medical education have had only limited impact. Disease-...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.12.010

    authors: Colonna S,Sweetenham J,Burgon TB,Buys SS,Lynch R,Au T,Johnson E,Kubal T,Paculdo D,Acelajado MC,Peabody JW

    更新日期:2019-04-01 00:00:00

  • JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.

    abstract:BACKGROUND:Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased surviva...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.05.006

    authors: Chen M,Pockaj B,Andreozzi M,Barrett MT,Krishna S,Eaton S,Niu R,Anderson KS

    更新日期:2018-10-01 00:00:00

  • Use of Adjuvant Breast Hypofractionation Radiation Treatment at a Cancer Center in Ontario From 2011 to 2018.

    abstract:BACKGROUND:The adoption of hypofractionated radiotherapy (HFRT) into clinical practice varies widely despite randomized trials and guidelines supporting its equivalence to conventional fractionated radiotherapy (CFRT) for certain patient populations. We assessed the use of HFRT at a single institution from 2011 to 2018...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.03.006

    authors: Lam E,Chan S,Karam I,Lee J,Wong G,Zhang L,Vesprini D,Wronski M,Chin L,Razvi Y,McKenzie E,Rakovitch E,Chow E

    更新日期:2020-10-01 00:00:00

  • The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

    abstract::Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Su...

    journal_title:Clinical breast cancer

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3816/CBC.2002.n.020

    authors: Vogel VG,Costantino JP,Wickerham DL,Cronin WM,Wolmark N

    更新日期:2002-06-01 00:00:00

  • Prevalence of Ectopic Breast Tissue and Tumor: A 20-Year Single Center Experience.

    abstract:BACKGROUND:Ectopic breast tissue, which includes both supernumerary breast and aberrant breast tissue, is the most common congenital breast abnormality. Ectopic breast cancers are rare neoplasms that occur in 0.3% to 0.6% of all cases of breast cancer. PATIENTS AND METHODS:We retrospectively report, using a large seri...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.03.004

    authors: Famá F,Cicciú M,Sindoni A,Scarfó P,Pollicino A,Giacobbe G,Buccheri G,Taranto F,Palella J,Gioffré-Florio M

    更新日期:2016-08-01 00:00:00

  • Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology.

    abstract:BACKGROUND:Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer. PATIENTS AND METHODS:We ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2017.08.004

    authors: Azim HA,Abdel-Malek R,Kassem L

    更新日期:2018-04-01 00:00:00

  • Dietary Habits and Physical Activity are Associated With the Risk of Breast Cancer Among Young Iranian Women: A Case-control Study on 1010 Premenopausal Women.

    abstract:BACKGROUND:Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or li...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.10.011

    authors: Fararouei M,Iqbal A,Rezaian S,Gheibi Z,Dianatinasab A,Shakarami S,Dianatinasab M

    更新日期:2019-02-01 00:00:00

  • Impact of NCI Socioeconomic Index on the Outcomes of Nonmetastatic Breast Cancer Patients: Analysis of SEER Census Tract-Level Socioeconomic Database.

    abstract:PURPOSE:To assess the impact of National Cancer Institute socioeconomic status (SES) index on breast cancer-specific survival (BCSS) of nonmetastatic breast cancer patients registered within the Surveillance, Epidemiology and End Results (SEER) census tract-level SES database. PATIENTS AND METHODS:The census tract-lev...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.06.013

    authors: Abdel-Rahman O

    更新日期:2019-12-01 00:00:00

  • ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance.

    abstract::According to the World Health Organization (WHO) published data in 2015; breast cancer is the most prevalent and the second leading cause of cancer death among females. As approximately 70% of breast cancer tumor cells are estrogen receptor (ER) positive, primary therapeutic agents such as Anti-estrogens were produced...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2017.03.013

    authors: Teymourzadeh A,Mansouri S,Farahmand L,Hosseinzade A,Majidzadeh-A K

    更新日期:2017-10-01 00:00:00

  • Implant-sparing Mastectomy: An Alternative for Women Undergoing Mastectomy With Retropectoral Implants.

    abstract:INTRODUCTION:Implant-sparing mastectomy (ISM) is a skin-sparing mastectomy that preserves a retropectoral implant and potentially eliminates the need for tissue expansion or complex reconstruction. This study aimed to determine oncologic and surgical outcomes and reconstructive patterns in patients undergoing ISM. PAT...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.08.007

    authors: Burke EE,Laronga C,Sun W,DeBiase S,Naqvi SMH,Fridley B,Czerniecki BJ,Hoover SJ,Khakpour N,Kiluk JV,Lee MC

    更新日期:2020-02-01 00:00:00

  • Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma.

    abstract:BACKGROUND:Triple-negative breast carcinoma is defined by a primary tumor that is estrogen receptor negative, progesterone receptor negative, and HER2 negative. The current study was performed to determine the relationship of triple-negative tumor status to outcome after breast conservation treatment with radiation. P...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2009.n.018

    authors: Solin LJ,Hwang WT,Vapiwala N

    更新日期:2009-05-01 00:00:00

  • Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients.

    abstract:BACKGROUND:Intensive chemotherapy confers benefit to patients with high-risk early breast cancer (BC). We characterized the feasibility and toxicity profile of anthracycline-containing adjuvant chemotherapy (ACAC) in older women with early BC. PATIENTS AND METHODS:Available data from women who received ACAC for BC in ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.12.001

    authors: Karavasilis V,Papadimitriou C,Gogas H,Kouvatseas G,Pentheroudakis G,Koutras A,Christodoulou C,Bafaloukos D,Samantas E,Pisanidis N,Papakostas P,Aravantinos G,Karanikiotis C,Kosmidis P,Pectasides D,Dimopoulos MA,Fountzilas

    更新日期:2016-08-01 00:00:00

  • Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).

    abstract::In addition to classical clinicopathologic factors, such as hormone receptor positivity, human epidermal growth factor receptor 2 (HER2) status, and tumor size, grade, and lymph node status, a number of commercially available genomic tests may be used to help inform treatment decisions for early breast cancer patients...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2020.01.001

    authors: Kittaneh M,Badve S,Caldera H,Coleman R,Goetz MP,Mahtani R,Mamounas E,Kalinsky K,Lower E,Pegram M,Press MF,Rugo HS,Schwartzberg L,Traina T,Vogel C

    更新日期:2020-06-01 00:00:00

  • Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.

    abstract::Chemotherapeutic agents that disrupt the assembly or disassembly of microtubules, including paclitaxel and docetaxel, are among the most commonly prescribed anticancer therapies. However, the utility of taxane-based therapy is limited principally by problems with formulation, slow administration, cumulative neurotoxic...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2008.s.001

    authors: Andreopoulou E,Muggia F

    更新日期:2008-03-01 00:00:00

  • CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

    abstract:BACKGROUND:This meta-analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin-dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) disease. METHODS:We ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clbc.2018.04.017

    authors: Deng Y,Ma G,Li W,Wang T,Zhao Y,Wu Q

    更新日期:2018-10-01 00:00:00

  • Aromatase inhibitors for the treatment and prevention of breast cancer.

    abstract::In a review of current information on aromatase inhibitors (AIs) and their use in breast cancer treatment and prevention, published reports were obtained through a Medline search. Tamoxifen, a selective estrogen receptor modulator, is approved for use in metastatic breast cancer (MBC), the adjuvant treatment of breast...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2005.n.006

    authors: Kalidas M,Brown P

    更新日期:2005-04-01 00:00:00

  • Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.

    abstract:BACKGROUND:This study aimed to investigate the use of nonpegylated liposomal doxorubicin (NPLD) in the management of metastatic breast cancer (MBC) within routine UK clinical practice and to assess its efficacy and tolerability. PATIENTS AND METHODS:All patients that received NPLD for MBC at 5 institutions were identi...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2013.10.011

    authors: Palmieri C,Misra V,Januszewski A,Yosef H,Ashford R,Keary I,Davidson N

    更新日期:2014-04-01 00:00:00

  • Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of georgia tumor registry.

    abstract:BACKGROUND:Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. PATIENTS AND METHODS:Data were obtained from the Medical College of Georgia Tumor Regi...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2010.n.008

    authors: Barcenas CH,Wells J,Chong D,French J,Looney SW,Samuel TA

    更新日期:2010-02-01 00:00:00